Taken together, preclinical data from mouse and zebrafish models of Scn1a‐related Dravet syndrome is in line with clinical efficacy data for stiripentol and its combinations with other ASMs in this DEE. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.